These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
342 related articles for article (PubMed ID: 27585244)
1. Alternative lengthening of telomeres does exist in various canine sarcomas. Kreilmeier T; Sampl S; Deloria AJ; Walter I; Reifinger M; Hauck M; Borst LB; Holzmann K; Kleiter M Mol Carcinog; 2017 Mar; 56(3):923-935. PubMed ID: 27585244 [TBL] [Abstract][Full Text] [Related]
2. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas. Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas. Liau JY; Lee JC; Tsai JH; Yang CY; Liu TL; Ke ZL; Hsu HH; Jeng YM Mod Pathol; 2015 Dec; 28(12):1545-54. PubMed ID: 26428317 [TBL] [Abstract][Full Text] [Related]
4. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Ulaner GA; Hoffman AR; Otero J; Huang HY; Zhao Z; Mazumdar M; Gorlick R; Meyers P; Healey JH; Ladanyi M Genes Chromosomes Cancer; 2004 Oct; 41(2):155-62. PubMed ID: 15287028 [TBL] [Abstract][Full Text] [Related]
5. Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome. Liau JY; Tsai JH; Jeng YM; Lee JC; Hsu HH; Yang CY Am J Surg Pathol; 2015 Feb; 39(2):236-44. PubMed ID: 25229770 [TBL] [Abstract][Full Text] [Related]
6. Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres. Bower K; Napier CE; Cole SL; Dagg RA; Lau LM; Duncan EL; Moy EL; Reddel RR PLoS One; 2012; 7(11):e50062. PubMed ID: 23185534 [TBL] [Abstract][Full Text] [Related]
9. Differential nuclear ATRX expression in sarcomas. Koelsche C; Renner M; Johann P; Leiss I; Sahm F; Schimmack S; Wardelmann E; Renker EK; Schirmacher P; Korshunov A; von Deimling A; Mechtersheimer G Histopathology; 2016 Apr; 68(5):738-45. PubMed ID: 26291601 [TBL] [Abstract][Full Text] [Related]
10. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Henson JD; Hannay JA; McCarthy SW; Royds JA; Yeager TR; Robinson RA; Wharton SB; Jellinek DA; Arbuckle SM; Yoo J; Robinson BG; Learoyd DL; Stalley PD; Bonar SF; Yu D; Pollock RE; Reddel RR Clin Cancer Res; 2005 Jan; 11(1):217-25. PubMed ID: 15671549 [TBL] [Abstract][Full Text] [Related]
11. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors. VandenBussche CJ; Allison DB; Graham MK; Charu V; Lennon AM; Wolfgang CL; Hruban RH; Heaphy CM Cancer Cytopathol; 2017 Jul; 125(7):544-551. PubMed ID: 28371511 [TBL] [Abstract][Full Text] [Related]
12. Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function. Macha SJ; Koneru B; Burrow TA; Zhu C; Savitski D; Rahman RL; Ronaghan CA; Nance J; McCoy K; Eslinger C; Reynolds CP Cancer Res; 2022 Sep; 82(18):3345-3358. PubMed ID: 35947641 [TBL] [Abstract][Full Text] [Related]
13. Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations. Farooqi AS; Dagg RA; Choi LM; Shay JW; Reynolds CP; Lau LM J Neurooncol; 2014 Aug; 119(1):17-26. PubMed ID: 24792489 [TBL] [Abstract][Full Text] [Related]
14. Alternative Lengthening of Telomeres Is Rare in Canine Histiocytic Sarcoma. Kreilmeier-Berger T; Aupperle-Lellbach H; Reifinger M; Hörstke NV; Holzmann K; Kleiter M Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686490 [TBL] [Abstract][Full Text] [Related]
15. Functional Loss of Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308 [TBL] [Abstract][Full Text] [Related]
16. Human sarcomas are mosaic for telomerase-dependent and telomerase-independent telomere maintenance mechanisms: implications for telomere-based therapies. Gocha AR; Nuovo G; Iwenofu OH; Groden J Am J Pathol; 2013 Jan; 182(1):41-8. PubMed ID: 23260199 [TBL] [Abstract][Full Text] [Related]
17. ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner. Brosnan-Cashman JA; Yuan M; Graham MK; Rizzo AJ; Myers KM; Davis C; Zhang R; Esopi DM; Raabe EH; Eberhart CG; Heaphy CM; Meeker AK PLoS One; 2018; 13(9):e0204159. PubMed ID: 30226859 [TBL] [Abstract][Full Text] [Related]
18. DNA methylation mediated up-regulation of TERRA non-coding RNA is coincident with elongated telomeres in the human placenta. Novakovic B; Napier CE; Vryer R; Dimitriadis E; Manuelpillai U; Sharkey A; Craig JM; Reddel RR; Saffery R Mol Hum Reprod; 2016 Nov; 22(11):791-799. PubMed ID: 27604461 [TBL] [Abstract][Full Text] [Related]
19. Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas. Ahvenainen TV; Mäkinen NM; von Nandelstadh P; Vahteristo MEA; Pasanen AM; Bützow RC; Vahteristo PM Cancer; 2018 Dec; 124(24):4650-4656. PubMed ID: 30423196 [TBL] [Abstract][Full Text] [Related]
20. Clinical features of ATRX or DAXX mutated neuroblastoma. Kurihara S; Hiyama E; Onitake Y; Yamaoka E; Hiyama K J Pediatr Surg; 2014 Dec; 49(12):1835-8. PubMed ID: 25487495 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]